Healthcare professionals typically initiate GLP-1 therapy at a low dose and increase gradually over several weeks
Still, some early clinical findings hint at potential uses in more specific contexts: Perioperative brain protection: A randomized controlled trial involving 155 liver surgery patients found that ALA reduced oxidative brain injury from anesthesia (sevoflurane) and improved cognitive recovery scores after surgery.31 Neurodegenerative conditions: In a small trial, ALA appeared to slow brain atrophy in patients with secondary progressive multiple sclerosis over a two-year period.32 While promising, this outcome still needs further confirmation
All three metabolite concentration values in the ACC were significantly reduced in this group
most patients find this effect welcome Digestive changes constipation, loose stools, or mild bloating are common early on Fatigue occasionally reported in the first few weeks Injection site reactions mild itching or redness, typically resolves quickly Side effects are managed through gradual dose titration starting at a low dose and increasing slowly over several weeks
DGAT overexpression increased the lifespan of yeast [49], whereas DGAT1 depletion in female mice prolonged the lifespan of the mice and protected against age-onset obesity [50]
An 8-week cycle might follow this pattern: 2 weeks introduction, 4 weeks optimization, 2 weeks maintenance
